

4.0.3 DOC Cmte minutes

Dementia Guideline Committee meeting 12 – development

Date: 16/01/2017 & 17/01/17

Location: NICE offices, London

Minutes: Final



Committee members present:	
Damien Longson (DL) (chair)	Present for all
Louise Allan (LA)	Present for all
Kevin Minier (KMin)	Present for all
Jeremy Isaacs (JI)	Present for all
Linda Clare (LC)	Present for all
Hannah Luff (HL)	Present for day 1
Richard Clibbens (RC)	Present for all
Sandra Evans (SE)	Present until day 2, item 5
Chris Roberts (CR)	Present for all
Joanne Brady (JB)	Present for all
John O'Brien (JO)	Present for all
Louise Robinson (LR)	Present for all
Tracey Wright (TW)	Present for all
Karen Harrison-Denning (KHD)	Present for all

In attendance:		
Joshua Pink (JP)	ICG – Technical Advisor	Present for all
Vicky Gillis (VG)	ICG – Technical Analyst	Present for all
Marie Harrisingh (MH)	ICG – Technical Analyst	Present for all
Toby Mercer (TM)	ICG – Technical Analyst	Present for all
Sohaib Ashraf (SA)	ICG – Health Economist	Present for all
Angela Parkin (AP)	NICE Medicines Advisor	Present for all
Elizabeth Barrett (EB)	NICE Information Specialist	Present for all
Daniel Davies (DD)	ICG - Project Manager	Present for all
Rupert Franklin (RF)	NICE – Guideline commissioning manager	Present for all

Observers:	
Danielle Conroy	NICE – Coordinator (Social care)

4.0.3 DOC Cmte minutes

Christina Barnes	NICE – Coordinator (Commissioning)
Jayne Roberts	Lay member carer

Apologies:

Carol Duff (CD)	Committee member
Ruth O’Dea (RO)	Committee member
Paul Dunnery (PD)	Committee member
Sarah Partington (SP)	Co-opted member
Gabriel Rogers (GR)	ICG – Health Economic Advisor
Susan Ellerby (SE)	ICG – Clinical Adviser
Sue Spiers (SS)	ICG – Associate Director

Day 1 – 16 January 2017

1. Welcome, apologies, objectives for the meeting, declaration of interests and minutes of previous meeting

The Chair welcomed the Committee members and attendees to the twelfth meeting of the dementia guideline committee.

Apologies for the meeting were received as detailed above.

The Chair outlined the proposed objectives of the meeting and asked each attendee to declare any new conflicts.

- JI declared an interest relating to his work as Principal Investigator for the CREAD clinical trial of Crenezumab versus placebo for prodromal and mild Alzheimer’s disease. Commercial study sponsored by Roche. He received no remuneration.

No other committee members declared any new interests.

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2 & 3. Update from the Social Care Subgroup, review and ratification of Social Care subgroup recommendations

JP and TW provided an update on the last meeting of the Social Care subgroup and presented the recommendations made for comment and ratification.

Following discussion, the committee agreed to defer ratification of the recommendations until the next meeting.

4. Review Question 14: What models of palliative care are effective for people with

4.0.3 DOC Cmte minutes

dementia?

TM recapped the review protocol and presented the evidence supporting review question 14 for the committee's consideration.

Following the presentation the committee discussed the evidence and drafted nine recommendations.

5. Any other business

DL reminded the committee of the start time for the next day's meeting.

Day 2 – 17 January 2017

1. Welcome, apologies, objectives for the meeting, declaration of interests and minutes of previous meeting

The Chair welcomed the Committee members and attendees to day two of the meeting.

Apologies for the meeting were received as detailed above.

The Chair outlined the proposed objectives of the meeting and asked each attendee to declare any new conflicts since day one.

No committee members declared any new interests.

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Update on Review Question 31 & 32

MH presented an additional piece of evidence relating to RQ 31 and 32.

The committee discussed the evidence and chose to make no changes to their recommendations.

3. Review Question 19: What are the most effective tools to identify drugs that may be causing cognitive decline?

VG recapped the review protocol and presented the evidence supporting review question 14 for the committee's consideration.

Following the presentation the committee discussed the evidence and drafted two recommendations.

5. Review Question 20: What are the most effective methods of differentiating dementia or dementia and delirium from delirium alone?

4.0.3 DOC Cmte minutes

MH recapped the review protocol and presented the evidence supporting review question 14 for the committee's consideration.

Following the presentation the committee discussed the evidence and drafted four recommendations and one research recommendation.

5. Any other business

DL reminded the committee of the date of the next meeting and the topics for discussion. The committee agreed amended start times for future two day meetings.

Date of next meeting: Thursday 02 and Friday 03 March 2017

Location of next meeting: NICE offices, London